{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T16:01:52Z","timestamp":1788624112817,"version":"build-2803163510"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Neuroleptic malignant syndrome (NMS), thought to arise through dopamine antagonism, is life-threatening. While prompt diagnosis of NMS is critical, it may be obscured by other diagnoses, such as malignant catatonia, with overlapping, life-threatening symptoms. Initiation of dopamine-blocking agents such as antipsychotics and abrupt cessation of dopaminergic medications such as amantadine can precipitate NMS. Once NMS is suspected, deft medical management should ensue. Multiple case reports detail electroconvulsive therapy\u2019s (ECT\u2019s) effectiveness in the treatment of NMS. While this relationship is well-documented, there is less literature regarding comparative efficacy of ECT in the acute treatment of NMS-like states precipitated by withdrawal of dopamine agonists, such as amantadine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case<\/jats:title><jats:p>We present a 52-year-old female with schizoaffective disorder bipolar type, with a history of a lorazepam-resistant catatonic episode the prior year that had responded to amantadine. She presented febrile with altered mental status, lead pipe rigidity, mutism, grasp reflex, stereotypy, autonomic instability, and a Bush-Francis Catatonia Rating Scale (BFCRS) of 24, suggesting malignant catatonia versus NMS. There was concern over a potentially abrupt cessation of her amantadine of which she had been prescribed for the past year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Organic etiologies were ruled out, and a presumptive diagnosis of NMS was made with central dopaminergic depletion from abrupt dopamine agonist (amantadine) withdrawal as the suspected underlying etiology. After intravenous lorazepam and reinduction of amantadine failed to alleviate her symptoms, urgent ECT was initiated. Our patient received an index series of ECT of seven treatments. After ECT #1 she was no longer obtunded, after treatment #2 her symptoms of mutism, rigidity, stereotypy, and agitation showed improvement, and by ECT #3, the NMS had rapidly dissipated as evidenced by stable vital signs, lack of rigidity, and coherent conversation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Brisk identification of potentially life-threatening NMS and NMS-like states, including malignant catatonia, warrants a trial of ECT. ECT\u2019s theoretical mechanisms of action coincide with the theoretical pathophysiology of the conditions. It is a viable and safe treatment option for reducing mortality. With prompt initiation of ECT, we obtained rapid control of a condition with a potentially high mortality.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1143407","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T05:33:57Z","timestamp":1679549637000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Rapid symptom control in neuroleptic malignant syndrome with electroconvulsive therapy: A case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Lauren","family":"Katzell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Beydler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00edlcar Silva","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Vijayvargiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent R.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1017\/s1092852900013365","article-title":"The universal field hypothesis of catatonia and neuroleptic malignant syndrome","volume":"5","author":"Carroll","year":"2000","journal-title":"CNS Spectr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.tjem.2017.10.001","article-title":"A retrospective analysis of cases with neuroleptic malignant syndrome and an evaluation of risk factors for mortality","volume":"17","author":"Sahin","year":"2017","journal-title":"Turk J Emerg Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1440-1819.2009.02042.x","article-title":"Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death","volume":"64","author":"Tural","year":"2010","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1192\/bjp.165.4.548","article-title":"Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shut-down hypothesis","volume":"165","author":"Osman","year":"1994","journal-title":"Br J Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/pnp.412","article-title":"Multiple episodes of NMS: overlap with malignant catatonia","volume":"20","author":"Hardy","year":"2016","journal-title":"Prog Neurol Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1192\/pb.26.5.197-a","article-title":"Catatonia and neuroleptic malignant syndrome","volume":"26","author":"Chaplin","year":"2002","journal-title":"Psychiatr Bull"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S2215-0366(18)30474-7","article-title":"Structure and neural mechanisms of catatonia","volume":"6","author":"Walther","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1600-0447.1996.tb09814.x","article-title":"Rating scale and standardized examination","volume":"93","author":"Bush","year":"1996","journal-title":"Acta Psychiatr Scand"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.9758\/cpn.2015.13.2.218","article-title":"Recurrent idiopathic Catatonia: implications beyond the diagnostic and statistical manual of mental disorders 5th edition","volume":"13","author":"Caroff","year":"2015","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref10","first-page":"243","article-title":"General anesthesia after neuroleptic malignant syndrome","volume":"18","author":"Lotstra","year":"1983","journal-title":"Biol Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.genhosppsych.2013.04.009","article-title":"Prevalence and clinical correlations of catatonia in older adults referred to a liaison psychiatry service in a general hospital","volume":"35","author":"Jaimes-Albornoz","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/med\/9780199329311.003.0014","article-title":"Catatonia, neuroleptic malignant syndrome, and serotonin syndrome","volume-title":"Psychosomatic medicine","author":"Azzam","year":"2015"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2011.02.012","article-title":"Measuring catatonia: a systematic review of rating scales","volume":"135","author":"Sienaert","year":"2011","journal-title":"J Affect Disord"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.schres.2013.04.034","article-title":"Catatonia in DSM-5","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/1941875210386491","article-title":"Neuroleptic malignant syndrome: a review for neurohospitalists","volume":"1","author":"Berman","year":"2011","journal-title":"Neurohospitalist"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5498\/wjp.v5.i2.182","article-title":"Electroconvulsive therapy in catatonic patients: efficacy and predictors of response","volume":"5","author":"Luchini","year":"2015","journal-title":"World J Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/YCT.0000000000000600","article-title":"Electroconvulsive therapy for neuroleptic malignant syndrome: a case series","volume":"35","author":"Morcos","year":"2019","journal-title":"J ECT"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5498\/wjp.v6.i4.391","article-title":"Catatonia: our current understanding of its diagnosis, treatment and pathophysiology","volume":"6","author":"Rasmussen","year":"2016","journal-title":"World J Psychiatry."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/NDT.S147897","article-title":"Systematic review of catatonia treatment","volume":"14","author":"Pelzer","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"993671","DOI":"10.3389\/fnmol.2022.993671","article-title":"Molecular and cellular mechanisms leading to catatonia: an integrative approach from clinical and preclinical evidence","volume":"15","author":"Ariza-Salamanca","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"22cr03394","DOI":"10.4088\/PCC.22cr03394","article-title":"COVID-19-Associated Benzodiazepine-Resistant Catatonia Responds to Amantadine","volume":"24","author":"Oh","year":"2022","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1192\/apt.2.4.151","article-title":"Neuroleptic malignant syndrome","volume":"2","author":"Kohen","year":"1996","journal-title":"Adv Psychiatr Treat"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1176\/ajp.2007.164.6.870","article-title":"Neuroleptic malignant syndrome","volume":"164","author":"Strawn","year":"2007","journal-title":"Am J Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2190\/X0FF-VU7G-QQP7-L5V7","article-title":"Somatic treatment of catatonia","volume":"25","author":"Hawkins","year":"1995","journal-title":"Int J Psychiatry Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/j.1440-1614.1999.00630.x","article-title":"Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases","volume":"33","author":"Trollor","year":"1999","journal-title":"Aust N Z J Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/j.1875-9114.1986.tb03475.x","article-title":"Neuroleptic-induced catatonia after abrupt withdrawal of amantadine during neuroleptic therapy","volume":"6","author":"Brown","year":"1986","journal-title":"Pharmacotherapy"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/01.yct.0000159325.08303.45","article-title":"Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome","volume":"21","author":"Ozer","year":"2005","journal-title":"J ECT"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jad.2022.01.048","article-title":"Repetitive transcranial magnetic stimulation for obsessive-compulsive disorder: a systematic review and pairwise\/network meta-analysis","volume":"302","author":"Fitzsimmons","year":"2022","journal-title":"J Affect Disord"},{"key":"ref29","first-page":"1301","article-title":"Anticonvulsant and antidepressant properties of electroconvulsive therapy: a proposed mechanism of action","volume":"18","author":"Sackeim","year":"1983","journal-title":"Biol Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1056\/NEJMra2034954","article-title":"Electroconvulsive therapy","volume":"386","author":"Espinoza","year":"2022","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.psc.2020.11.003","article-title":"Use of electroconvulsive therapy in autism","volume":"44","author":"Park","year":"2021","journal-title":"Psychiatr Clin North Am"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"591","DOI":"10.4103\/1947-2714.145480","article-title":"Rapid response of long-standing, treatment-resistant non-catatonic mutism in paranoid schizophrenia with single ECT session","volume":"6","author":"Dar","year":"2014","journal-title":"N Am J Med Sci"},{"key":"ref33","first-page":"179","article-title":"ECT-induced and drug-induced hypomania","volume":"8","author":"Angst","year":"1992","journal-title":"Convuls Ther"},{"key":"ref34","first-page":"81","article-title":"Mania as a side effect of electroconvulsive therapy","volume":"4","author":"Andrade","year":"1988","journal-title":"Convuls Ther"},{"key":"ref35","first-page":"27","article-title":"ECT-induced mania","volume":"11","author":"Lee","year":"2014","journal-title":"Innov Clin Neurosci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4172\/2167-1044.1000123","article-title":"ECT in bipolar disorder: incidence of switch from depression to hypomania or mania","volume":"1","author":"Bost-Baxter","year":"2013","journal-title":"J Depress Anxiety"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00702-021-02389-x","article-title":"Implications of dopaminergic medication withdrawal in Parkinson\u2019s disease","volume":"129","author":"Koschel","year":"2022","journal-title":"J Neural Transm"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/BF03161096","article-title":"Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome","volume":"5","author":"Brantley","year":"2009","journal-title":"J Med Toxicol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/PRA.0000000000000237","article-title":"The role of amantadine withdrawal in 3 cases of treatment-refractory altered mental status","volume":"23","author":"Fryml","year":"2017","journal-title":"J Psychiatr Pract"},{"key":"ref40","first-page":"415","article-title":"Lamotrigine increases gene expression of GABA-A receptor \u03b23 subunit in primary cultured rat hippocampus cells","author":"Wang","year":"2002"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.pnpbp.2008.03.004","article-title":"The effect of lamotrigine on platelet monoamine oxidase type B activity in patients with bipolar depression","volume":"32","author":"Muck-Seler","year":"2008","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12888-020-02597-x","article-title":"Lamotrigine, quetiapine and aripiprazole-induced neuroleptic malignant syndrome in a patient with renal failure caused by lithium: a case report","volume":"20","author":"Szota","year":"2020","journal-title":"BMC Psychiatry"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1176\/appi.neuropsych.11040093","article-title":"Lamotrigine-induced neuroleptic malignant syndrome under risperidone treatment: a case report","volume":"24","author":"Motomura","year":"2012","journal-title":"JNP"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/WNF.0b013e318294799a","article-title":"Neuroleptic malignant syndrome induced by lamotrigine","volume":"36","author":"Ishioka","year":"2013","journal-title":"Clin Neuropharmacol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1143407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T05:34:04Z","timestamp":1679549644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1143407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":44,"alternative-id":["10.3389\/fpsyt.2023.1143407"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1143407","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"article-number":"1143407"}}